NEW YORK (AP) — U.S. regulators have declined to approve Bristol-Myers Squibb's daclatasvir as part of a combination hepatitis C treatment with another antiviral drug called asunaprevir. The company says data it submitted to the Food and Drug Administration to win approval of daclatasvir focused on that drug's use with asunaprevir. However, the New York-based drugmaker in October withdrew its application for approval of asunaprevir.Read more on NewsOK.com